• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

AEterna Zentaris

edit

AEterna Zentaris Inc. is a drug development company specialized in oncology and endocrine therapy. The Company’s product pipeline encompasses compounds at all stages of development, from drug discovery through marketed products. The priorities in oncology are its Phase III program with perifosine in multiple myeloma and its Phase II program in multiple cancers, including metastatic colon cancer, as well as Phase II program with AEZS-108 in advanced endometrial and advanced ovarian cancer combined with potential developments in other cancer indications. In endocrinology, the Company’s program is the reactivation of a Phase III trial with AEZS-130 (SolorelTM) as a growth hormone (GH) stimulation test for the diagnosis of GH deficiency in adults (AGHD).

Recent Milestones

edit

• 
  AEterna Zentaris — Aeterna Zentaris snags $69M pact on perifosine (3/9/11)
  Posted 3/9/11 at 10:18pm via fiercebiotech.com
• 
  AEterna Zentaris added Jürgen Engel as President and CEO.
  Posted 3/9/11 at 10:16pm
• 
  Went public with stock symbol NASDAQ:AEZS.
  Posted 3/9/11 at 10:17pm
• 
  AEterna Zentaris added David A. Dodd as President and Chief Executive Officer.
  Posted 4/20/13 at 5:14am

Videos

Screenshots

edit

Above: AEterna Zentaris
Uploaded: 3/10/11

Stock Price

Sources

Aeterna Zentaris snags $69M pact on perifosine (fiercebiotech.com) [edit]